Printer Friendly

Novartis AG signs license with Anadys Pharmaceuticals to develop, commercialize new HCV, HCB treatments; completes Hexal acquisition.

Novartis AG, Basel, Switzerland, announced it has signed an exclusive global license agreement with Anadys Pharmaceuticals, San Diego, CA, for ANA975 and additional Toll-Like Receptor 7 (TLR7) oral prodrugs for the treatment of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV).

Under terms of the agreement, Novartis obtains the rights to develop, manufacture and commercialize NAN975 for HCV as well as develop the drug in additional infectious disease indications including HBV. ANA975, an organ prodrug of Anadys' small molecule compound isatoribine, belongs to a new class of drugs being developed to regulate innate immunity by interacting with TLR7. Novartis says ANA975 is currently in Phase I development for the treatment of HCV. Anadys successfully completed several proof of concept studies with isatoribine in HCV patients.

Under terms of the agreement, Novartis will make an initial license payment of $20 million to Anadys. Anadys is also eligible to receive up to $550 million in regulatory and commercial milestone payments based on the successful development and commercialization of ANA975. A $10 million payment is due following a successful Investigational New Drug Application (IND) submission, which Anadys expects to file with the FDA in the middle of 2005.

Contact: John Gilardi, Novartis AG - Phone: +41 61 324 3018, Web site: www.novartis.com; Pete De Spain - Phone: (858) 530-3653, Web site: www.anadyspharma.com
COPYRIGHT 2005 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 10, 2005
Words:223
Previous Article:FDA panel finds Chiron's cyclosporine inhalation solution safe, but evenly split on drug's efficacy.
Next Article:Oxford BioMedica, Viragen and Roslin Institute announce achievement in avian transgenic biomanufacturing.
Topics:


Related Articles
Novartis AG acquisition of Hexal AG, Eon Labs to become world's top generic drug maker.
Chiron, Enanta Pharmaceuticals sign agreement for developing, commercializing HCV therapeutics.
Anadys announces exclusive collaboration with Novartis to develop and commercialize therapeutics for Hepatitis C and Hepatitis B.
ANADYS INITIATES 28-DAY CLINICAL TRIAL OF ANA975.
Idenix licenses valopicitabine to Novartis.
Idenix licenses valopicitabine to Novartis.
Idenix reports Novartis exercises option to license compound for treating hepatitis C.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |